Navamedic Asa · OSL:NAVA
Navamedic Asa — Q1 2020 Earnings Presentation
22 slides from Navamedic Asa's earnings presentation, 2020
Slide 1: First quarter results 2020
2020 First quarter results 2020 Navamedic ASA Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Navamedic - Q1 2020 highlights
Navamedic - Q1 2020 highlights Strong growth across all product categories Imdur® back on track. Obesity, Medical Nutrition and new products delivering strong growth in the quarter REVENUE GROSS MARGIN EBITDA* Distribution agreement for ThermaCare® in the Nordics and Netherlands (historically around
Slide 3: Navamedic at a glance
Navamedic at a glance Nordic pharma company targeting growth in North Europe Navamedic - a reliable supplier of high-quality consumer health, medical nutrition, specialty pharma and branded generics products, delivered to hospitals and through pharmacies, meeting the specific medical needs for patie
Slide 4: Our growth strategy continues in 2020
Our growth strategy continues in 2020 Ambition of building a leading Nordic pharma company Alflorex® launched in targeting growth in North Europe Denmark (Q1 2020) and planned launch in the Netherlands 1 (2H 2020). TermaCare® to be STRENGTHEN THE CORE launched in July Untapping potential within exis
Slide 5: Growth in all key categories
New classification from Q1 2020 Growth in all key categories Medical nutrition Consumer health Branded generics Specialty pharma Medical nutrition Gastro, oral, dermatology, Cardiology, generics Obesity, urology product portfolio pain Q1 2020 YoY revenue growth: 37% Q1 2020 YoY revenue growth: 11% Q
Slide 6: Medical nutrition – Continued strong performance
Strengthen the core Medical nutrition – Continued strong performance GROWTH DRIVERS • Strong growth in products for inborn errors of protein metabolism Q1 2020 REVENUE • Good development of newly 14.5 MNOK launched products for the dietary treatment of (Q1 2019: 10.6 MNOK) Tyrosinemia type 1 (liver
Slide 7: Consumer Health - launch of new and unique products
Strengthen the core Consumer Health - launch of new and unique products GROWTH DRIVERS • Alflorex® launched in Norway in Q3 2019 and Denmark in Q1 Q1 2020 REVENUE 2020. Launching in the Iceland Q2 and Netherlands in 2H 2020 7.9 MNOK • Continued growth for GeloRevoice® (25%) (Q1 2019: 7.1 MNOK • Excl
Slide 8: Specialty pharma – Continued strong performance
Strengthen the core Specialty pharma – Continued strong performance GROWTH DRIVERS Q1 2020 REVENUE • New reimbursable 12.7 MNOK prescription in Norway • New marketing platform (Q1 2019: 9.8 MNOK) and patient support program 8
Slide 9: Financials
Financials
Slide 10: Key consolidated profit and loss figures
Financials A strong quarter with 22% revenues Key consolidated profit and loss figures growth over last year Gross profit margin of 28.3% is negatively affected by: (in NOK million) Q1 2020 Q1 2019 Year 2019 - Currency impact (approx. Operating revenues 55.6 45.4 188.8 1.5-2.0 ppt) Gross profit 15.7
Slide 11: Assets
Financials Increase in Goodwill from 31.12.2019 is currency related Assets Investment in associated company is the equity investment in Observe Medical, reduced by (in NOK million) 31.03.2020 31.03.2019 31.12.2019 estimated Q1 result Intangible assets 7.6 27.7 6.6 Goodwill 64.3 89.2 59.5 Loans to as
Slide 12: Equity and liabilities
Financials Equity and liabilities Equity ratio of 46% (in NOK million) 31.03.2020 31.03.2019 31.12.2019 Increase in Equity is mainly due Equity 125.5 101.3 79.2 to cash increase from the Contingent consideration 0.0 12.7 0.0 private placement in Q1 Long term part of license liabilities 12.7 10.1 9.6
Slide 13: Cash flow Group – total operations
Financials Cash flow Group – total operations Net cash from Operating (in NOK million) Q1 2020 Q1 2019 Year 2019 activities is mostly due to net Net cash flow from operating activities -15.3 9.2 12.7 result and changes in working capital Net cash flow from investing activities -1.0 -0.3 -1.9 Net cas
Slide 14: Summary and outlook
Summary and outlook
Slide 15: Summary and outlook
Navamedic ASA Summary and outlook Summary and outlook Building a leading Nordic pharma company targeting growth in North Europe In Q1 2020, we have • Strengthened the core by driving growth across the portfolio • Expanded our portfolio through exclusive distribution rights for ThermaCare, our first
Slide 16: Q&A
Q&A @ Navamedic
Slide 17: Thank you for your attention!
Thank you for your attention! Presentation of Navamedic’s Q2 2020 and H1 2020 report will be on 20 August, 2020
Slide 18: Appendix
Appendix
Slide 19: Condensed consolidated statement of comprehensive income
Appendix Condensed consolidated statement of comprehensive income (in NOK '1000) Q1 2020 Q1 2019 Year 2019 Operating revenues 55 642 45 432 188 755 Cost of materials -39 920 -33 035 -131 152 Gross profit 15 722 12 396 57 603 Gross profit % 28.3 % 27.3 % 30.5 % Payroll expense -7 514 -7 142 -33 363 O
Slide 20: Condensed consolidated statement of cash flows
Appendix Condensed consolidated statement of cash flows (in NOK '1000) Q1 2020 Q1 2019 Year 2019 Profit/loss(-) before tax for total operations -12 166 -5 106 -24 488 Taxes paid -653 -285 329 Depreciation, amortization and write off 842 1 921 5 769 Interest and contingent consideration without cash
Slide 21: Basis for preparation; Definitions of Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 22: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any